AIM ImmunoTech (NYSE:AIM) Releases Earnings Results

AIM ImmunoTech (NYSE:AIMGet Free Report) released its quarterly earnings data on Thursday. The company reported ($0.12) earnings per share for the quarter, reports. AIM ImmunoTech had a negative return on equity of 191.38% and a negative net margin of 16,123.32%. The firm had revenue of $0.04 million for the quarter.

AIM ImmunoTech Stock Up 3.3 %

NYSE:AIM opened at $0.40 on Friday. The firm’s fifty day moving average price is $0.44 and its two-hundred day moving average price is $0.44. The company has a current ratio of 1.14, a quick ratio of 1.68 and a debt-to-equity ratio of 0.23. AIM ImmunoTech has a one year low of $0.32 and a one year high of $0.75.

Insider Buying and Selling at AIM ImmunoTech

In other AIM ImmunoTech news, CEO Thomas K. Equels purchased 61,729 shares of the stock in a transaction that occurred on Monday, May 6th. The shares were acquired at an average cost of $0.41 per share, with a total value of $25,308.89. Following the completion of the transaction, the chief executive officer now owns 778,184 shares in the company, valued at $319,055.44. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CEO Thomas K. Equels bought 61,729 shares of AIM ImmunoTech stock in a transaction dated Monday, May 6th. The shares were bought at an average cost of $0.41 per share, with a total value of $25,308.89. Following the acquisition, the chief executive officer now owns 778,184 shares in the company, valued at approximately $319,055.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Thomas K. Equels purchased 75,758 shares of the company’s stock in a transaction that occurred on Friday, March 15th. The stock was bought at an average cost of $0.33 per share, with a total value of $25,000.14. Following the purchase, the chief executive officer now owns 716,455 shares of the company’s stock, valued at $236,430.15. The disclosure for this purchase can be found here. Insiders have purchased a total of 335,603 shares of company stock valued at $120,464 in the last three months. 0.02% of the stock is currently owned by company insiders.

AIM ImmunoTech Company Profile

(Get Free Report)

AIM ImmunoTech Inc, an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS).

Recommended Stories

Earnings History for AIM ImmunoTech (NYSE:AIM)

Receive News & Ratings for AIM ImmunoTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIM ImmunoTech and related companies with MarketBeat.com's FREE daily email newsletter.